Henrique Faneca

Dr. Henrique Faneca

Center for Neurosciences and Cell Biology (CNC), Coimbra, Portugal
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2001 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
MLMaria Monteiro Pedroso De Lima
Maria Monteiro Pedroso De Lima
SSSérgio Simões
Sérgio Simões
PPPedro Pires
Pedro Pires
Henrique FanecaHenrique Faneca
Henrique Faneca
NDNejat Düzgüneş
Nejat Düzgüneş

1 March 2005 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
SSSérgio Simões
Sérgio Simões
AFAna Filipe
Ana Filipe
Henrique FanecaHenrique Faneca
Henrique Faneca
MMMiguel Mano
Miguel Mano
NPNuno Penacho
Nuno Penacho
MLMaria Monteiro Pedroso De Lima
Maria Monteiro Pedroso De Lima
Cationic liposome–DNA complexes (lipoplexes) constitute a potentially viable alternative to viral vectors for the delivery of therapeutic genes. This review will focus on various parameters governing lipoplex biological activity, from their mode of formation to invivo behaviour. Particular emphasis is given to the mechanism of interaction of lipoplexes with cells, in an attempt to dissect the different barriers that need to be surpassed for efficient gene expression to occur. Aspects related to new trends in the formulation of lipid-based gene delivery systems aiming at overcoming some of their limitations will be covered. Finally, examples illustrating the potential of ca-tionic liposomes in clinical applications will be provided.

20 July 2011 in Biomacromolecules
Verified
Journal Article
Closed access
MMMaria Moura
Maria Moura
Henrique FanecaHenrique Faneca
Henrique Faneca
MLMaria Monteiro Pedroso De Lima
Maria Monteiro Pedroso De Lima
MGM. Helena Gil
M. Helena Gil
MFM. Margarida Figueiredo
M. Margarida Figueiredo

1 November 2012 in Cancer Letters
Verified
Journal Article
Closed access
SDSónia Duarte
Sónia Duarte
GCGeorges Carle
Georges Carle
Henrique FanecaHenrique Faneca
Henrique Faneca
MLMaria Monteiro Pedroso De Lima
Maria Monteiro Pedroso De Lima
VPValérie Pierrefite-Carle
Valérie Pierrefite-Carle

1 September 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
RCRosemeyre A. Cordeiro
Rosemeyre A. Cordeiro
ASArménio Serra
Arménio Serra
JCJorge Coelho
Jorge Coelho
Henrique FanecaHenrique Faneca
Henrique Faneca

25 November 2022 in Journal of Controlled Release
Verified
Journal Article
Open access
IPInês S. Pinto
Inês S. Pinto
RCRosemeyre A. Cordeiro
Rosemeyre A. Cordeiro
Henrique FanecaHenrique Faneca
Henrique Faneca
Chimeric antigen receptor T cell (CAR T cell) therapy is a revolutionary approach approved by the FDA and EMA to treat B cell malignancies and multiple myeloma. The production of these T cells has been done through viral vectors, which come with safety concerns, high cost and production challenges, and more recently also through electroporation, which can be extremely cytotoxic. In this context, nanosystems can constitute an alternative to overcome the challenges associated with current methods, resulting in a safe and cost-effective platform. However, the barriers associated with T cells transfection show that the design and engineering of novel approaches in this field are highly imperative. Here, we present an overview from CAR constitution to transfection technologies used in T cells, highlighting the lipid- and polymer-based nanoparticles as a potential delivery platform. Specifically, we provide examples, strengths and weaknesses of nanosystem formulations, and advances in nanoparticle design to improve transfection of T cells. This review will guide the researchers in the design and development of novel nanosystems for next-generation CAR T therapeutics.